Regeneron Pharmaceuticals Inc.

09/19/2021 | Press release | Distributed by Public on 09/19/2021 09:52

ESMO Late-breaking Data Show Libtayo® (cemiplimab) and Chemotherapy First-line Treatment Combination Significantly Improved Overall Survival in Patients with Advanced NSCLC